Studies of single-dose toxicity of radiolabeled nanoparticle Fe3O4@Lapatinib - 153Sm in animals

  • Nguyễn Thị Kim Dung Bệnh viện Trung ương Quân đội 108
  • Phạm Thành Minh Viện Nghiên cứu hạt nhân
  • Phạm Đăng Tùng Bệnh viện ĐKQT Vinmec Times city
  • Nguyễn Quốc Thắng Bệnh viện ĐKQT Vinmec Times city
  • Hán Tuấn Ngọc Bệnh viện Trung ương Quân đội 108
  • Mai Hồng Sơn Bệnh viện Trung ương Quân đội 108

Main Article Content

Keywords

Radiolabeled nanoparticles, Sm-153, single-dose toxicity

Abstract

Objective: The study was conducted to evaluate single-dose toxicity of radiolabeled nanoparticles Fe3O4@Lapatinib - 153Sm produced at DaLat Nuclear Research Institute on Swiss mice. Subject and method: Radiolabeled nanoparticles Fe3O4@Lapatinib - 153Sm was injected to Swiss mice were injected the doses up to 100 times higher than the equivalent human dose according to the European Medicines Agency (EMA) guidelines for single-dose toxicity testing method for microdoses of active ingredients and OECD guidelines for acute toxicity studies. Result: The results of single-dose toxicity in Swiss mice at a dose of 20 times higher than the human dose at 24 hours after injection showed a statistically significant difference between the test group and the control group in term of biochemical, hematological and histopathological parameter. The functional recovery in the testing animals injected with radioactive nanoparticles was observed 14 days post-injection. Conclusion: The radiolabeled nanoparticles Fe3O4@Lapatinib - 153Sm has caused toxicity to organ and physiological metabolism of mice at 24 hours post-injection, however, functional recovery to normal levels was observed after 14 days. The product needs to be further studied to improve its physiochemical properties for preclinical research in the furture

Article Details

References

1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F (2021) Cancer statistics for the year 2020: An overview. International journal of cancer 149(4): 778-789.
2. Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH (2012) Lapatinib for advanced or metastatic breast cancer. The oncologist 17(4): 536-542.
3. Bahreyni A, Mohamud Y, Luo H (2020) Emerging nanomedicines for effective breast cancer immunotherapy. Journal of nanobiotechnology 18 (1): 1-14.
4. Ganesan K, Wang Y, Gao F, Liu Q, Zhang C, Li P, Zhang J, Chen J (2021) Targeting engineered nanoparticles for breast cancer therapy. Pharmaceutics 13(11): 1829.
5. Organisation for Economic Co-operation and Development (2008) Test No, 425: Acute oral toxicity: Ip-and-down procedure. OECD publishing.
6 European Medicines Agency (2008) ICH topic M3 (R2) non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. European Medicines Agency London, United Kingdom.
7. Organisation for Economic Co-operation and Development (2002) Test no, 423: acute oral toxicity-acute toxic class method. OECD publishing.
8. Agency, European Medicines (2008) Human medicine European public assessment report (EPAR): Tyverb.
9. Agency, European Medicines (1998) Human medicine European public assessment report (EPAR): Quadramet.